On March 28, 2024, Gilead Sciences announced that it has filed a definitive proxy statement with Securities and Exchange Commission stating that it has received a shareholder proposal from Jing Zhao requesting the Company to reform the board structure to include one member of board of directors from the Company?s non-management employees. In addition, the Company urged the shareholders to vote against the shareholder proposal at its annual general meeting of shareholders scheduled to be held on May 8, 2024
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
65.94 USD | +0.79% | -1.51% | -18.60% |
02:31pm | Barclays Adjusts Price Target on Gilead Sciences to $76 From $80 | MT |
Apr. 26 | TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.60% | 81.58B | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences Files a Definitive Proxy Statement